Novavax, Inc.

万万没想到，刚刚过去的三个月时间里，辉瑞的新冠药物Paxlovid卖了27.03亿美元，新冠疫苗Comirnaty卖了14.22亿美元。 没错，仅三个月时间，辉瑞的新冠药物+疫苗的销售额，就高达41.25亿美元。 这可能是，新冠疫情翻篇后，对于辉瑞和新冠药物最好的消息。要知道，去年以来新冠药物销售额的断崖式暴跌，让市场对其商业价值充满怀疑。如今，辉瑞却拿出了媲美流感的成绩单。 流感疫苗是全球疫苗界的重磅品种，疫苗巨头赛诺菲、GSK去年全球的流感疫苗销售额分别为26.69亿欧元（约28.8亿美元）和5.04亿英镑（6.2亿美元）；流感药物方面，奥司他韦原研药达菲早已走下神坛，东阳关的可威靠着颗粒制剂一跃成为流感“神药”，去年销售额超过50亿元人民币。 然而，这三大流感药物顶流，去年全年的销售总额，才与辉瑞的新冠药物堪堪打个平手。 基于过去几年新冠与流感秋冬共流行时造成的更大医疗负担，以及美国免疫实践咨询委员会（ACIP）今年的建议来看，今后新冠的免疫将与流感趋于一致，即倾向于进行每年一次的季节性免疫和根据对流行毒株的监测结果的必要更新。 某种程度上，这也在坐实新冠“大号”流感的商业地位。 一个不争的事实是，新冠的危害远超流感。在商业逻辑等同的情况下，新冠药物的市场前景，理应更胜一筹。 那么问题来了，国内企业是否做好了准备？ 01 三季度卖了41亿美元 2022年，新冠疫苗和新冠口服药为辉瑞带来了高达570亿美元的收入。靠着新冠产品带来的泼天富贵，这一年辉瑞的收入突破1000亿美元，刷新了大药企的收入最高纪录。 然而，随着新冠疫情的消散，全球市场对新冠产品的需求都出现了断崖式下跌，辉瑞首当其冲。面对“新冠悬崖”，辉瑞不得不持续调低收入预期。 而今年三季报，辉瑞却交出了一份远超市场预期的成绩单。三季度营收达177亿美元，同比增长31%，远超市场一致预期的149亿美元，这主要得益于Eliquis、Paxlovid和Vyndaqel系列药物的强劲表现。 其中，得益于近期新冠肺炎疫情带来的市场需求、美国政府4.42亿美元的订单，Paxlovid的销售额创下27亿美元的新高，同比增长了25亿美元。对此，辉瑞强调，虽然去年这一时期没有销售额，但今年二季度抗病毒药物的收入仅为2.51亿美元，反映了季度的大幅增长。三季度，Comirnaty收入则为14亿美元，同比增长9%。 可以看出，无论是Paxlovid还是疫苗，市场需求都颇为强劲。 核心在于，新冠疫情并未彻底消失，三季度美国夏季新冠感染病例的意外激增。如下图所示，根据美国疾病控制与预防中心（CDC）报告的废水中新冠病毒监测，7月份正是美国疫情的一个高峰期，感染后寻求药物治疗的人数必然激增。 图片来源：氨基观察 同时，经历新一轮疫情小高峰，面临即将到来的秋冬病毒季节，接种新冠疫苗的需求也有所增长。这也使得，自9月开放疫苗接种仅4周，美国新冠更新疫苗（2024-2025年版）就已达到11.2%，大幅高于2023年同期。 美国CDC更新到10月25日的数据显示，接种更新的2024─25新冠疫苗的人口百分比为儿童4.8%，18岁以上成年人为13.5%，其中65岁以上成年人为30.4%。去年，仅有约22.5%的成年人接种了秋季发布的新冠疫苗。 当然，由于种种原因，美国如今的新冠疫苗接种率也并不算高。作为对比，同期美国成人流感疫苗接种率已经超过40%。但是，经历过去两年疫情的折磨，人们对于新冠特效药还是颇为认可的，毕竟这能帮助部分人缓解病痛、降低风险，尤其高危人群。 一方面，所有人都知道了新冠病毒的威力，而从疗效来看，Paxlovid是当前全球最能打的口服药之一，且年初FDA已经通过了其新药上市申请（NDA），用于治疗12岁以上轻度至中度新冠患者。作为对比，默沙东的Molnupiravir作为全球首款上市的新冠口服药，至今仍是紧急使用授权（EUA）。 另一方面，出于疫情防控需要，2023年中之前，Paxlovid在美国是经由政府采购、免费发放至市民手中。尽管由于疫情逐渐消散，美国政府大批退货Paxlovid，导致辉瑞不得不在2023年四季度扣减35亿美元的营收，但美国政府的“免费”推广，还是为Paxlovid树立了不错的口碑。加上辉瑞的商业化措施，使得在这一波新冠疫情小高峰下，Paxlovid销量大增。 02 “大号”流感 事实上，尽管新冠疫苗的接种率远远低于流感疫苗，但大家都清楚，新冠感染带来的潜在危险大于流感。 新冠作为一个新出现的人类传染病，从流行开始至WHO于2023年5月5宣布新冠作为全球公共卫生紧急状态（PHE）结束，三年多的时间全球共有正式报告的病例7.76亿例，死亡人数超706万。 这还只是正式向WHO报告的病例和死亡数，实际死亡和病例数要远超过这些。 虽然流感和新冠对大多数人来说是一种自限性感染，但对于小孩、老人、孕妇和由于各种原因导致的免疫功能低于正常成年人的人群，二者感染都可能会导致严重的疾病或死亡。因此，疫苗和药物都是刚需。 而从美国ACIP今年的建议来看，今后新冠的免疫将与流感趋于一致，即倾向于进行每年一次的季节性免疫和根据对流行毒株的监测结果的必要更新。 某种程度上，这也在坐实新冠“大号”流感的地位。这也让新冠药物的商业化逻辑向流感靠拢。 先来看疫苗。 流感疫苗市场规模可观的原因在于两点：自主定价和持续性接种需求。目前看，这也正在成为新冠疫苗的商业化逻辑。 定价方面，海外新冠疫苗的定价在120美元-130美元间，远高于流感疫苗价格（50美元-90美元），疫苗企业拥有丰厚的利润空间； 而由于新冠和流感这类RNA病毒都是逃脱大师，始终在突变躲避机体的免疫防御机制，因此，新冠疫苗也需要像流感疫苗那样每年更新毒株，重新配制，接种者也需要每年重复接种。 8月份，FDA批准了辉瑞和Moderna研发的新冠疫苗的更新版本，针对的是KP.2（JN.1分支）变种，因为最近的大多数新冠病例都是由该毒株引起；另外，Novavax生产的基于JN.1毒株的新冠疫苗也获批上市。 由于病毒变异的持续性，我们只是利用实时监测手段，尽可能减少疫苗株和流行株之间的差异。从9月份CDC新冠监测结果看，现在的流行优势毒株和今年用的疫苗株仍属于JN1分支,与去年流行的XBB差别较大。 因此，去年根据XBB制作的疫苗，CDC今年已经不推荐使用。这也是实时监测流行优势毒株的意义所在。 再来看口服药。 对抗流感病毒，靠的是口服药和疫苗的通力合作。而在流感口服药中，最为人所熟知的要数奥司他韦。 1999年到2017年，奥司他韦原研药达菲为罗氏带来至少150亿美元的收入。其中，仅2009年的销售额就超过了30亿美元。但随着仿制药入场，达菲早已走下神坛。 而在国内，早早拿到专利授权的东阳光药，通过剂型创新，使可威早已远超达菲，成为一度年销售额达60亿元的流感“神药”。 对于新冠口服药来说，由于全球疫情肆虐，出道即巅峰。而当疫情回归平稳或常态化状态，其市场前景则取决于两点，药物专利和疗效。 在疗效方面，Paxlovid也证明过自己并获得了市场认可。而在专利方面，辉瑞也在加紧布局，以期建立一个“Paxlovid专利墙”。 2021年，辉瑞加入了非营利组织MPP，在全球95个中低收入国家放弃Paxlovid专利权，但其也计划在61个国家和4个地区专利局提交Paxlovid专利申请。 Paxlovid是一种新化合物nirmatrelvir（PF-07321332）和一种老药ritonavir的组合。其中，ritonavir的主要专利（化合物、多晶体等）已经过期，PF-07321332则是一个全新分子。 根据《辉瑞Paxlovid专利地图》报告，截至2022年，辉瑞已经在34个国家递交了Paxlovid专利申请。市场猜测，由于专利格局尚未完全成熟，辉瑞可能会或已经提交了后续申请，以延长潜在的保护期（组合、剂量方案、进一步使用、多型等）。 如果按照其2021年8月6日的PCT国际申请日期，此类授予专利的预计到期日期为2041年8月5日，这不包括专利期限的延长。 这也意味着，辉瑞有足够的时间，赚取利润。 03 新的投入与竞争 无论如何，正如前文所说，不管是破坏力还是传播性，新冠的威力都要远超过流感。在商业逻辑等同的情况下，新冠药物的市场前景，理应更胜一筹。 这也是为什么，仅三个月时间，辉瑞的新冠药物+疫苗的销售额，能够高达41.25亿美元。 换句话说，只要新冠病毒不像当初的SARS病毒般自我消失，那么新冠药物的商业价值超越流感，也将是一个大概率事件。 然而，当海外新冠药物在自费市场证明其商业价值之际，国内企业似乎还在“爬坡”。 就国内来说，新冠依旧反复流行。如下图所示，根据中国疾病预防控制中心10月发布的《全国新型冠状病毒感染疫情情况（2024年9月）》，今年出现了两波新冠高峰，分别出现在3月及7-8月份。 图片来源：氨基观察 对比来看，新冠病毒阳性率峰值远低于去年往期，处于历史低点，但新冠依然存在。 然而，从已上市企业公布的信息来看，尚无一款新冠产品，如Paxlovid般在新一波疫情袭来的背景下崭露头角，大多产品在财报中早已隐去踪迹。 先来看疫苗。 自2024年7月15日起，国内新冠病毒疫苗不再免费接种，调整为自费接种。然而，当前新冠疫苗的价格基本都高于当前流感疫苗价格。 根据山东省药械集中采购平台8月份公布的数据，价格最低的鼻喷流感病毒载体新冠肺炎疫苗，由万泰生物生产，0.2毫升/支的价格为136元；价格最高的是吸入用重组新型冠状病毒XBB.1.5变异株疫苗，由康希诺生产，0.5毫升/支（3次人用剂量）的价格为1114元，单次价格为371.3元。其他几款疫苗单次价格均在300元左右。 另外，根据安徽省公布的2024年新冠病毒疫苗采购目录，相同产品价格与黑龙江省、山东省类似，安徽还将石药集团的mRNA疫苗（Omicron XBB.1.5）纳入，价格为598元/瓶。 这样的自费价格显然会影响接种意愿。加之对疫苗的错误认知，如接种疫苗后仍被病毒感染，导致新冠疫苗接种率并不高。 企业层面，或许是出于对自费市场的低预期，一些疫苗企业并未继续投入新冠疫苗。 比如康希诺，最新三季报显示，总营收5.67亿元，同比增长36.85%（剔除新冠疫苗退货对去年同期造成的影响），增长主要来自流脑疫苗产品，销售占比达到91%。日前，在接受《证券时报》采访中，康希诺董事长宇学峰表示，经过了这两年的消化，逐渐将新冠的“包袱”卸下了。 再来看口服药。 疫情期间，国内批准了6款小分子新冠药物附条件上市。除了Paxlovid和Molnupiravir这2款高价进口药物，还有阿兹夫定、民得维、先诺欣和乐睿灵4款国产药物。 相比疫苗产品被“战略抛弃”，口服药还得到了部分药企的重视。比如民得维，君实生物在其半年报中表示，1月被正式纳入国家医保目录，截至报告期末，民得维已进入超过2300家医院。 再比如先诺欣。7月，先声药业宣布，先诺欣由附条件批准转为常规批准，这也是目前国内首个且唯一获得常规获批的抗新冠口服药。 正式获批后，最显著的变化就是购药会变为便利，即患者可以通过处方在药店自行购买。这会带来怎样的竞争变化，还需时间的验证。 事实上，疫情管控放开后，大多数人经历过2到3次新冠感染，现在基本已经不拿新冠当回事，主观感觉新冠药物失去用武之地，但正如前文所说，无论疫苗还是口服药对于免疫低下等人群，仍十分重要。 着眼未来，只要病毒不消失，新冠药物的需求必然不是问题，影响天花板的问题，自然就成了药企如何提高自费疫苗接种率，以及药物是否能如流感药般成为家庭常备用药。而这需要持续的疫苗研发、生产投入，以及药物商业化推广。 新冠药物到底行不行？这又是一场新的投入与竞争。 来源 | 氨基观察（药智网获取授权转载） 撰稿 | 武月 责任编辑 | 八角 声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。 商务合作 | 王存星 19922864877（同微信）  阅读原文，是受欢迎的文章哦

VANCOUVER, BC, Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats. The RRPV is a multiple-purpose acquisition vehicle to facilitate end-to-end development of future medical countermeasures, from the early stage through the advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The RRPV is designed to foster and accelerate the speed of acquisition and partnerships in response to pandemics and other biothreat incidents and promotes innovation and rigorous development of medical countermeasures and enabling technologies to further enhance national health security. A principal focus of the RRPV is to enable targeted product development expertise specifically for vaccines and therapeutics. Proposals are solicited from consortium members for individual project requirements on behalf of BARDA, which will evaluate proposals and authorize RRPV to issue project agreements with Consortium members for individual projects. The RRPV complements BARDA's existing solicitation and acquisition vehicles such as the Broad Agency Announcement (BAA) and will expand the mechanisms through which BARDA can rapidly partner with product developers in fields of interest to BARDA, such as improved flu vaccines and platform technologies that enable expedited turn-around for vaccine development. BioVaxys President and Chief Operating Officer Kenneth Kovan, says, "We are pleased to join the RRPV consortium with organizations including AstraZeneca, Battelle, Deutsches Zentrum für Infektionsforschung e.V. (The German Center for Infection Research), Genentech, Ginkgo Bioworks, Inc., Novavax and Leidos. We believe DPX can play a major role in the development of BARDA's priority vaccine programs, and having the ability to collaborate with such world-renowned consortium members will no doubt be a significant benefit for the Company." BioVaxys Technology Corp. () is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX-rPA for anthrax, DPX-flu for influenza, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed "James Passin" James Passin, Chief Executive Officer Phone: +1 646 452 7054 Cautionary Statements Regarding Forward-Looking Information This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Logo: SOURCE BioVaxys Technology Corp. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus, a new study shows. Survival rates for organ recipients one and three years after the procedure were the same for donors with or without HIV. Also the same were risks of serious side effects, such as infection, fever, and rejection in the donated organ. In what is the largest comparative trial of the experimental procedures since the first transplant was performed in the United States in 2016, researchers at NYU Langone Health say their study findings further support formally adopting the use of organs from donors with HIV as standard clinical practice for people with HIV in need of kidney transplantation. Spurred by a worldwide shortage of organ donors, the U.S. Congress passed the HIV Organ Policy Equity Act, or HOPE Act, in 2013, paving the way for first efforts to learn if kidney donors with HIV could safely donate to recipients who also tested positive for the virus. Nearly 90,000 Americans are currently on waiting lists for kidney transplantation, and those in need of a kidney transplant who are HIV positive are more than twice as likely to die while waiting than those who are HIV negative. HIV-to-HIV transplantation has not been formally accepted as the standard of care. Concerns existed about organ recipients becoming infected with other strains of HIV, potentially leading to so-called HIV superinfection. Experts also initially feared that recipients' need for ongoing postsurgical immunosuppression would damage either the donated organ or lead to resurgence of the recipient's HIV viral blood counts. A serious complication in all transplantation is that the recipient's immune system will recognize the donated organ as "foreign" and attack it, much like it would an invading virus. For this reason, immune-suppressing drugs are used to prevent organ-transplant rejection. However, early success with HIV-to-HIV kidney transplantation alleviated these concerns. Publishing in the New England Journal of Medicine online Oct. 17, researchers analyzed the outcomes for 198 kidney transplantations to people with HIV at 26 medical centers across the U.S. from 2018 to 2021. Results showed that for kidney transplants performed using organs from 99 donors with HIV and 99 without HIV, one-year survival rates for HIV-positive recipients were the same (at 94% and 95%, respectively). Three-year survival rates were also similar (at 85% and 87%). Organ rejection rates were also numerically on par after three years (at 21% and 24%.) Other measures for surgical outcomes, including the number of side effects that occurred, were also roughly the same for both groups. While most of the study's kidney recipients maintained viral suppression of HIV posttransplant, HIV blood counts spiked in 13 patients who received kidneys from donors with HIV. Just four such resurgent spikes occurred with organs from donors who were HIV negative. However, the researchers attributed these incidences to recipients' not taking their antiviral medications as prescribed, and viral suppression returned with tighter adherence to drug treatment. One superinfection was detected, but with no clinical effects on the organ recipient. "Our study demonstrates overwhelmingly that kidney transplantation from donors who are HIV positive to HIV-positive recipients is safe and effective," said study senior investigator and transplant surgeon Dorry Segev, MD, PhD. Segev is vice chair in the Department of Surgery at NYU Grossman School of Medicine and director of its Center for Surgical and Transplant Applied Research (C-STAR). Segev also helped draft the HOPE Act and advocated for its passage. His team also performed the first HIV-to-HIV kidney transplantation at Johns Hopkins, where he worked previously. "Thanks to the HOPE Act and this NIH-funded multicenter trial, our research offers clear evidence for moving kidney transplantation in people with HIV from the experimental phase to standard clinical practice and updating guidelines accordingly," said Segev, who is also a professor in the Departments of Surgery and Population Health at NYU Grossman. "These findings offer hope for the thousands of people with HIV in the U.S. and around the world who are in need of kidney transplantation, and to many more people where HIV infection and kidney diseases are more common," said Segev. The U.S. Department of Health and Human Services in September proposed policy changes to make HIV-to-HIV transplantation the standard of care for both kidney and liver donors. Segev says more research is needed to determine the safety and effectiveness of transplanting other organs, such as the heart and lungs, from HIV-positive donors. Funding for the study was provided by National Institutes of Health grants R01AI120938, R01DK131926, U01AI134591, U01AI138897, U01AI1772111, and R01DK101677. Segev has served as a consultant for pharmaceutical and healthcare companies AstraZeneca, CareDx, Moderna Therapeutics, Novavax, and Regeneron, and has received speaker fees and honoraria from Springer Publishing, AstraZeneca, CareDx, Houston Methodist, Northwell Health, Optum Health Education, Sanofi, and WebMD. None of these groups were involved in the current study. The terms and conditions of all of these relationships are being managed in accordance with the policies and procedures of NYU Langone Health. Besides Segev, other NYU researchers involved in this study are Sapna Mehta, MD, and Alan Massie, PhD. Other researchers involved in the study are co-lead investigator Christine Durand, MD; and co-investigators Tao Liang, PhD; Diane Brown, BSN; Darin Ostrander, PhD; Yolanda Eby, MS; Niraz Jesai, MD; Fizza Naqvi, MD; Serena Bagnasco, MD; Andrew Redd, PhD; and co-senior investigator Aaron Tobian, MD, PhD, at Johns Hopkins Medicine in Baltimore, Md. Other study co-investigators are Sander Florman, MD, and Meenakshi Rana, MD, at the Icahn School of Medicine at Mount Sinai in New York City; Rachel Friedman-Moraco, MD, at Emory University in Atlanta; Alexander Gilbert, MD, at Georgetown University in Washington, DC; Peter Stock, MD, at the University of California, San Francisco; Shikha Mehta, MD, at the University of Alabama at Birmingham; Valentina Stosor, MD, at Northwestern University in Chicago; Marcus Pereira, MD, MPH, at Columbia University in New York City; Michele Morris, MD, at the University of Miami in Florida; Jonathan Hand, MD, at Ochsner Health in New Orleans; Saima Aslam, MD, MS, at the University of California San Diego in La Jolla; Maricar Malinas, MD, at Yale University in New Haven, Conn.; Ghady Haidar, MD, at the University of Pittsburgh in Pennsylvania; Catherine Small, MD, at Weill Cornell Medicine in New York City; Carlos Santos, MD, MPH, at Rush University in Chicago; Joanna Schaenman, MD, PhD, at the University of California, Los Angeles; John Baddley, MD, at the University of Maryland in Baltimore; David Wojciechowski, DO, at the University of Texas Southwestern in Dallas; Emily Blumberg, MD, at the University of Pennsylvania in Philadelphia; Karthik Ranganna, MD, at Drexel University in Philadelphia; Oluwafisayo Adebiyi, MD, at Indiana University in Indianapolis; Nahel Elias, MD, at Massachusetts General Hospital in Boston; Jose Castillo-Lugo, MD, at Methodist Health System in Dallas; Emmanuouil Giorgakis, MD, at the University of Arkansas in Little Rock; Senu Apewokin, MD, at the University of Cincinnati in Ohio;; Natasha Watson, BSN, MD; Erica Brittain, PhD; and Johan Odim, MD, PhD, at the National Institutes of Health in Bethesda, Md. Media Inquiries David March 212-404-3528 [email protected] SOURCE NYU Langone Health System WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED